Zobrazeno 1 - 10
of 1 089
pro vyhledávání: '"Masafumi Fukagawa"'
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Phosphate binders (PBs) generally have a high pill burden. Tenapanor selectively inhibits sodium/hydrogen exchanger isoform 3, reducing intestinal phosphate absorption. Tenapanor is a novel drug administered as a small tablet, twice daily. T
Externí odkaz:
https://doaj.org/article/dee01fcb98474a0a84ec5fbf0fbd2899
Autor:
Yuki Ohashi, Masao Toyoda, Nobumichi Saito, Masahiro Koizumi, Genta Kanai, Hirotaka Komaba, Moritsugu Kimura, Takehiko Wada, Hiroo Takahashi, Yuichiro Takahashi, Naoto Ishida, Takatoshi Kakuta, Masafumi Fukagawa, Kimiyoshi Ichida
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Two-thirds of urate is excreted via the renal pathway and the remaining one-third via the extra-renal pathway, the latter mainly via the intestine in healthy individuals. ABCG2, a urate exporter, is expressed in various tissues including the
Externí odkaz:
https://doaj.org/article/0e483fa5cdb84734b9795fd2b63716f9
Autor:
Jun Ito, Moritsugu Kimura, Tomoyuki Toya, Konomi Isozumi, Atsuro Kawaji, Yudai Isozaki, Masafumi Fukagawa
Publikováno v:
Renal Replacement Therapy, Vol 8, Iss 1, Pp 1-9 (2022)
Abstract Background The mortality rate of novel coronaviral disease (COVID-19) patients undergoing dialysis is considerably higher than that of patients with normal kidney function. As of August 2021, only remdesivir has been approved in Japan as an
Externí odkaz:
https://doaj.org/article/26c67d1ee856469c8358bdeb69d3ce00
Publikováno v:
Kidney International Reports, Vol 7, Iss 2, Pp 177-188 (2022)
Introduction: Simplified, but effective, hyperphosphatemia treatments with novel mechanisms of action, tolerable safety profiles, and low pill burden are needed for patients undergoing hemodialysis. Tenapanor is a calcium (Ca)-free, nonmetal, nonpoly
Externí odkaz:
https://doaj.org/article/48210c61531d4a239a5482b91c800fc1
Autor:
Steven Fishbane, Martin Ford, Masafumi Fukagawa, Kieran McCafferty, Anjay Rastogi, Bruce Spinowitz, Konstantin Staroselskiy, Konstantin Vishnevskiy, Vera Lisovskaja, Ayman Al-Shurbaji, Nicolas Guzman, Sunil Bhandari
Publikováno v:
BMC Nephrology, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Sodium zirconium cyclosilicate (SZC) is an effective and well-tolerated treatment for hyperkalemia in maintenance hemodialysis patients. In post-hoc analyses of the phase 3b DIALIZE study, we examined the spectrum of potassium res
Externí odkaz:
https://doaj.org/article/34d28eb0545844c79c1ba2ef8a4c4182
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract The ASTRIO study was a randomised, multicentre, 24-week study that compared the effects of ferric citrate hydrate (FC) and non-iron-based phosphate binders (control) on anaemia management in haemodialysis (HD) patients receiving erythropoies
Externí odkaz:
https://doaj.org/article/7705fdeb260f4bdd8e47266b578929ca
Autor:
Hiromasa Kato, Hiroshi Watanabe, Tadashi Imafuku, Nanaka Arimura, Issei Fujita, Isamu Noguchi, Shoma Tanaka, Takehiro Nakano, Kai Tokumaru, Yuki Enoki, Hitoshi Maeda, Shinjiro Hino, Motoko Tanaka, Kazutaka Matsushita, Masafumi Fukagawa, Toru Maruyama
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 6, Pp 1832-1847 (2021)
Abstract Background Sarcopenia with chronic kidney disease (CKD) progression is associated with life prognosis. Oxidative stress has attracted interest as a trigger for causing CKD‐related muscular atrophy. Advanced oxidation protein products (AOPP
Externí odkaz:
https://doaj.org/article/8e2b4ae67b8649ef93f2737fd499cb41
Publikováno v:
BMC Nephrology, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Fibroblast growth factor-23 (FGF23) and α-klotho are associated with anemia in patients with chronic kidney disease. In this post hoc analysis of the ASTRIO study (UMIN000019176), we investigated the relationship between FGF23 an
Externí odkaz:
https://doaj.org/article/75f8f795c9ba4dac989e29a7b7c58b1c
Autor:
Kazuyoshi Okada, Ken Tsuchiya, Ken Sakai, Takahiro Kuragano, Akiko Uchida, Kazuhiko Tsuruya, Tadashi Tomo, Chieko Hamada, Masafumi Fukagawa, Yoshindo Kawaguchi, Yuzo Watanabe, Kaoruko Aita, Yoshitatsu Ogawa, Junji Uchino, Hirokazu Okada, Yutaka Koda, Yasuhiro Komatsu, Hisamitsu Sato, Motoshi Hattori, Toru Baba, Mamiko Matsumura, Hisayuki Miura, Jun Minakuchi, Hidetomo Nakamoto, Committee for Updating the Proposal for Shared Decision Making on Initiation and Continuation of Dialysis, General Affairs Committee of the Japanese Society for Dialysis Therapy
Publikováno v:
Renal Replacement Therapy, Vol 7, Iss 1, Pp 1-23 (2021)
Abstract Background In Japan, forgoing life-sustaining treatment to respect the will of patients at the terminal stage is not stipulated by law. According to the Guidelines for the Decision-Making Process in Terminal-Stage Healthcare published by the
Externí odkaz:
https://doaj.org/article/94306aef3fa4431784a396bdf6c76954
Autor:
Hirotaka Komaba, Junhui Zhao, Suguru Yamamoto, Takanobu Nomura, Douglas S. Fuller, Keith P. McCullough, Pieter Evenepoel, Anders Christensson, Xinju Zhao, Mona Alrukhaimi, Fadwa Al‐Ali, Eric W. Young, Bruce M. Robinson, Masafumi Fukagawa
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 4, Pp 855-865 (2021)
Abstract Background Wasting is a common complication of kidney failure that leads to weight loss and poor outcomes. Recent experimental data identified parathyroid hormone (PTH) as a driver of adipose tissue browning and wasting, but little is known
Externí odkaz:
https://doaj.org/article/34aaf2d9903049db8e4dded1b0381dcf